Bayer Technology Services GmbH undertakes 3 yr liver study

Bayer Technology Services GmbH has announced plans to model the active transport of drugs in the liver in a trial stretching over the next few years, as part of QuantPro – an operation instigated by the Federal Ministry of Education and Research in Germany.

QuantPro – Quantitative analysis for the description of dynamic processes in living systems – forms part of the federal ministry’s biotechnology framework programme, Bayer Technology Services GmbH explains.

Allocated funding for the next three years, the trial is hoped to significantly improve the prediction of drug effects, while adding to the range of concepts and instruments available for the personalisation of drug therapies.

Jorg Lippert, head of systems biology at Bayer Technology Services GmbH, remarks: “As part of the QuantPro initiative, we have established a top-class consortium. Together, we are investigating one of the areas critical to the success or failure of drug therapies. Our work aims to improve the quality of the predictions which influence both development decisions at the pharmaceutical research stage and the choice of treatment made by clinicians.”

Last week the firm announced that in order to reduce both costs and complexity in its dealings, it intends to delist from the New York Stock Exchange.